Inspection Record

John W. Hollis Inc dba John Hollis Pharmacy — FDA 483 Findings

US FDAInspected 2015-07-10Published 2024-01-17 10 findingsAseptic processing and sterility assuranceStability and storageOther quality systemLaboratory and QC controlsEquipment and facilityMaterial and supplier control

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterlization process.Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterlization process.Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterlization process.

2Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

3Stability and storage

There is no written testing program designed to assess the stability characteristics ofdrug products.

4Other quality system

Clothing ofperwnnel engaged in tbe manufacturing, proeessing.

5Aseptic processing and sterility assurance

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to detennine conformance to such requirements.

6Aseptic processing and sterility assurance

Drug product containers and closures were not sterilized and processed to remove pyrogenic properties to assure that they are suitable fur their intended use.

7Laboratory and QC controls

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactor y conformance to a the final specifiction and identify and strength of each active ingredient prior to release.

8Equipment and facility

Buildings used .in rrns manufacture, processing, packing, or holding of a drug product do not have the suitable construction and location to facilitate cleaning, maintenance, and proper operations.

9Other quality system

Procedures describing the caligration of instructions, apparatus, gauges, and recording devicces are not written or followed.

10Material and supplier control

Each lot ofcomponents, drug product containers, aud closmes is not withheld from use until the Jot has been sampled.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

John W. Hollis Inc dba John Hollis Pharmacy company profile — full history US FDA documents, 2024 Go to Findings search